Who buys Mylan stock?
MYL stock was sold by a variety of institutional investors in the last quarter, including Regent Investment Management LLC, Oakbrook Investments LLC, Meeder Asset Management Inc., Gofen & Glossberg LLC IL, Crossmark Global Holdings Inc., City Holding Co. and Whittier Trust Co.. View Insider Buying and Selling for Mylan.
How can I get the latest Mylan news and ratings?
Sign-up to receive the latest news and ratings for Mylan and its competitors with MarketBeat's FREE daily newsletter.
Where can you buy MYL shares?
Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is the business model of Mylan?
Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products. It operates through two segments: Generic and Specialty. The Generic pharmaceutical business is conducted primarily in the U.S.
See more
Is Mylan stock a Buy, Sell or Hold?
Mylan stock has received a consensus rating of hold. The average rating score is and is based on 0 buy ratings, 2 hold ratings, and 0 sell ratings.
What was the 52-week low for Mylan stock?
For Mylan stock is no 52WeekLow data available or the value couldn't be calculated because of a value to close/at 0.00.
What was the 52-week high for Mylan stock?
For Mylan stock is no 52WeekHigh data available or the value couldn't be calculated because of a value to close/at 0.00.
What are analysts forecasts for Mylan stock?
The 2 analysts offering price forecasts for Mylan have a median target of 17.00, with a high estimate of 18.00 and a low estimate of 16.00. The med...
What is MarketBeat community rating?
What is Mylan N.V.?
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote “Outperform” if you believe MYL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.
What is the Mylan symbol?
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Where is Mylan located?
Mylan trades on the NASDAQ under the ticker symbol "MYL."
What is the P/E ratio of Mylan?
Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected].
Does Mylan pay dividends?
The P/E ratio of Mylan is 29.92, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.02.
Is Mylan a hold?
Mylan does not currently pay a dividend.
How Big Is Pfizer's Generic Drugs Business That It Plans To Merge With Mylan?
Wall Street analysts have given Mylan a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mylan wasn't one of them.
What is Mylan NV?
The combined entity could generate sales of over $20 billion by 2020, and Pfizer will hold a 57% stake in the new company, with Mylan holding the rest. In this note ...
What is an A rated stock?
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World.
What is Q factor score?
A-RATED STOCKS are those stocks the Big Data multi-factor models score as most probable to rise in price. These stocks are the best “BUYS” for investors.
Is Pfizer a Mylan?
The Q-Factor Score represents an expectation for how a stock will perform in a given month.
Does Quantalytics consider financial condition?
Pfizer (NYSE:PFE) today announced its plan to combine its generic drugs business with Mylan in a Reverse Morris Trust transaction. The combined entity could generate sales of over $20 billion by 2020, and Pfizer will hold a 57% stake in the new company, with Mylan holding the rest.
Is Quantalytics a third party?
Data, information, or opinions contained in Quantalytics in any form give no consideration to any particular individuals' investment needs or objectives, nor do they consider any individuals' financial condition. Consequently, any such data, information, or opinions do not in any way represent a personal recommendation to any individual investor or any entities, whatever the type.
About MYL
Any data, information, or opinions in Quantalytics in any form attributed to a third party represent Quantalytics’ interpretation of the data, information, or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.
Stats
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World.
How does MarketBeat calculate stock ratings?
Download the Public app to invest in this stock with any amount of money. Enter your cell phone number below to get started.
What does the blue line on the chart below mean?
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Does MarketBeat like Mylan?
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
When is Viatris conference 2021?
MarketBeat users like Mylan stock more than the stock of other Medical companies. 70.44% of MarketBeat users gave Mylan an outperform vote while medical companies recieve an average of 67.43% outperform votes by MarketBeat users.
What is a DNCD?
Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021. Chief Executive Officer Michael Goettler and Chief Financial Officer Sanjeev Narula will answer questions about the company at 9:10 a.m. ET.
When will Viatris release results?
Viatris Inc. (NASDAQ: VTRS) and The Defeat-NCD Partnership (DNCD) at The United Nations Institute for Training and Research (UNITAR) today signed a Memorandum of Understanding (MoU), focused on continuing cooperation and jointly utilising and leveraging their existing resources and facilities for programmes and initiatives aimed at addressing non-communicable diseases (NCDs) and their impacts on NCD patients as a result of COVID-19. This by focusing on enhancing care policies for prevention and treatment, particularly in assisting low- and middle-income countries to meet their UN Sustainable Development goals (SDG 3.4), to reduce NCD mortality by a third by 2030.
When is Viatris 2021?
Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2021 financial results on Monday, Aug. 9, before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 10 a.m. ET on Aug. 9 to discuss the results.
When is Viatris earnings call 2021?
Viatris Inc. (NASDAQ: VTRS) today announced the company will take part in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 .
Is Viatris a divestiture?
Viatris Inc to Host Earnings Call. NEW YORK, NY / ACCESSWIRE / May 10, 2021 / Viatris Inc (NASDAQ:VTRS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 10:00 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
Will Viatris stock return in 2022?
When it made its debut last November, Viatris ( VTRS) was touted as a value-unlocking divestiture. The pharmaceutical company, formed when Pfizer (PFE) merged its Upjohn unit with Mylan NV, started off trading for around $18 per share, but today it changes hands for around $13.46 per share.
Results
- Mylan NV (NASDAQ:MYL) posted its earnings results on Tuesday, May, 7th. The company reported $0.82 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.79 by $0.03. The business earned $2.50 billion during the quarter, compared to analyst estimates of $2.70 billion. Mylan had a return on equity of 18.96% and a net margin of 2.14%. The company'…
Performance
- Mylan updated its FY19 earnings guidance on Tuesday, May, 7th. The company provided earnings per share guidance of $3.80-4.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.42. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.96 billion.
Risks
- 20 brokerages have issued 1 year target prices for Mylan's shares. Their predictions range from $22.00 to $59.00. On average, they expect Mylan's share price to reach $37.5263 in the next year. This suggests a possible upside of 69.3% from the stock's current price. View Analyst Price Targets for Mylan.
Ratings
- 20 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Mylan in the last year. There are currently 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Mylan.
Reception
- Media headlines about MYL stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Myla…
Ownership
- Mylan saw a decrease in short interest in the month of April. As of April 15th, there was short interest totalling 8,795,009 shares, a decrease of 26.4% from the March 29th total of 11,953,722 shares. Based on an average daily trading volume, of 4,054,263 shares, the short-interest ratio is presently 2.2 days. Approximately 1.7% of the shares of the company are sold short. View Myla…
Business
- Mylan has a market capitalization of $11.43 billion and generates $11.43 billion in revenue each year. The company earns $352.50 million in net income (profit) each year or $4.58 on an earnings per share basis. Mylan employs 35,000 workers across the globe.